Carmustine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Carmustine: From Lymphoma and Brain Tumours to Lymph Node Cancer
One-Sentence Summary
Carmustine is a DNA-alkylating nitrosourea chemotherapy drug, originally used for lymphomas (Hodgkin and non-Hodgkin), brain tumours such as glioblastoma, and multiple myeloma. The TxGNN model predicts it may be effective for lymph node cancer, but the supporting evidence is weak: 1 clinical trial and 20 publications were found, and almost all of them concern high-dose chemotherapy in breast cancer with lymph node involvement, not a lymph node cancer. Carmustine is already used in established lymphoma regimens, so this is not a genuinely new use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Lymphomas (Hodgkin and non-Hodgkin), glioblastoma and other brain cancers, multiple myeloma. The Singapore registration data give no indication text, so this list comes from the TxGNN knowledge graph. |
| Predicted New Indication | Lymph node cancer |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L3. The one Phase 3 trial was terminated and studied breast cancer, so the L1 criterion is not met. |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug. Carmustine belongs to the nitrosourea class of alkylating agents. Its efficacy in lymphoma and brain tumours is established, and mechanistically it may apply to cancers of lymphoid tissue.
Carmustine is a core component of high-dose conditioning regimens given before autologous stem cell transplantation in lymphoma, such as BEAM and CBV. This is likely why the model links it to "lymph node cancer".
However, the label "lymph node cancer" is ambiguous. The evidence compiled for this prediction mostly concerns breast cancer patients with 4 to 10 or more involved axillary lymph nodes, treated with high-dose cyclophosphamide, cisplatin and carmustine plus stem cell rescue. That is a different disease. Only one paper (PMID 18988286) deals with a true lymph node malignancy, Hodgkin lymphoma, and it did not test carmustine as the variable. Any lymphoma use is largely already covered by existing labelled and established indications.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002772 | Phase 3 | Terminated | 602 | Intensive sequential chemotherapy (doxorubicin, paclitaxel, cyclophosphamide) vs high-dose chemotherapy with stem cell support in women with primary breast cancer and 4–9 involved axillary lymph nodes. Carmustine is not clearly an isolated variable, and the disease is not a lymphoma. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7577204 | 1995 | RCT | J Natl Cancer Inst Monogr | CALGB 9082: high-dose vs low-dose cyclophosphamide, cisplatin and carmustine as consolidation in breast cancer with ≥10 involved axillary nodes |
| 15767638 | 2005 | Randomized comparison | J Clin Oncol | High-dose chemotherapy with stem cell support vs intermediate-dose chemotherapy in high-risk primary breast cancer (CALGB 9082, SWOG 9114, NCIC MA-13) |
| 18988286 | 2008 | Randomized phase 2 | Cancer | Early vs late intensification in high-risk Hodgkin lymphoma. Five-year results of intensive chemotherapy plus low-dose lymph node radiotherapy vs ABVD plus autologous transplant. |
| 16118805 | 2005 | Randomized trial (QoL analysis) | Cancer | Quality of life after high-dose vs intermediate-dose chemotherapy in breast cancer with multiple positive nodes |
| 12523579 | 2002 | Phase II | Biol Blood Marrow Transplant | High-dose chemotherapy with hematopoietic support in breast cancer with 4–9 involved nodes |
| 15505610 | 2004 | Cohort | Biol Blood Marrow Transplant | Five-year results of high-dose cyclophosphamide, carmustine and thiotepa with stem cell transplant in high-risk breast cancer |
| 11895898 | 2002 | Cohort (pharmacokinetics) | Clin Cancer Res | Pharmacokinetics of high-dose cyclophosphamide, cisplatin and carmustine in relation to survival and toxicity in breast cancer |
| 2642573 | 1989 | Cohort | Leukemia | BCNU, etoposide and cyclophosphamide with autologous marrow transplant in 23 patients with advanced Hodgkin's disease |
| 36213836 | 2022 | Retrospective review | J Oncol | High-dose adjuvant chemotherapy with autologous transplant in locally advanced triple-negative breast cancer |
| 8484641 | 1993 | Clinical series | Am Rev Respir Dis | Pulmonary drug toxicity in 39% (23 of 59) of breast cancer patients after high-dose alkylator chemotherapy and marrow transplant |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN15502P | BiCNU-100MG (Carmustine for Injection USP 100 mg) and Dehydrated Alcohol Injection USP, combipack | Injection, powder, for solution |
| SIN13348P | Gliadel Wafer | Implant |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (nitrosourea alkylating agent) |
| Myelosuppression Risk | High. Myelosuppression is delayed and cumulative, with leukopenia and thrombocytopenia a major concern. |
| Emetogenicity Classification | High for intravenous dosing. Not applicable to the local wafer implant. |
| Monitoring Items | CBC with differential, pulmonary function (dose-related lung toxicity), liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please also refer to the package insert warnings and precautions.
Safety Considerations
- Contraindications / conditions of concern (from the knowledge graph, not label text): The TxGNN knowledge graph links carmustine to these conditions. Key examples are:
- Blood and marrow: thrombocytopenia, leukopenia, anaemia, acute leukaemias
- Lung: lung disease, pulmonary fibrosis
- Organs: kidney disease, liver disease, gallbladder disease
- Infection: infectious disease, fungal infection, meningitis, intracranial abscess
- Central nervous system: epilepsy, brain oedema, hydrocephalus, arachnoiditis
- Drug Interactions: 100 interactions were identified. Those with a graded severity are:
- Cimetidine (Major)
- Naltrexone (Moderate)
- Levofloxacin (Minor)
The remaining interactions have no graded severity. They include proton pump inhibitors, H2 blockers, corticosteroids, ondansetron, aprepitant, vancomycin and morphine.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence does not support lymph node cancer as a distinct new indication for carmustine. The single Phase 3 trial was terminated and studied breast cancer. The 20 papers mostly address high-dose regimens in breast cancer. Carmustine's role in true lymphoma (BEAM, CBV conditioning) is already established, so this prediction adds little beyond existing use.
To proceed, the following is needed:
- A precise definition of "lymph node cancer" (lymphoma subtype or nodal metastasis) to remove the ambiguity
- Lymphoma-specific trial and literature evidence in which carmustine is the tested variable
- Package insert warnings and contraindications for the Singapore-registered products, to enable a safety screen
- Mechanism of action data
- A safety plan covering pulmonary toxicity, myelosuppression and transplant-centre-only use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.